Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Up 2,767.7% in June

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the recipient of a large growth in short interest in June. As of June 15th, there was short interest totaling 493,245 shares, a growth of 2,767.7% from the May 31st total of 17,200 shares. Based on an average daily trading volume, of 5,161,875 shares, the short-interest ratio is currently 0.1 days. Currently, 0.6% of the shares of the stock are sold short.

Institutional Trading of Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC bought a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics at the end of the most recent reporting period. Institutional investors own 7.06% of the company’s stock.

Wall Street Analysts Forecast Growth

INDP has been the subject of a number of research analyst reports. Wall Street Zen upgraded shares of Indaptus Therapeutics to a “hold” rating in a research report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Indaptus Therapeutics presently has an average rating of “Sell”.

Indaptus Therapeutics Stock Performance

Shares of NASDAQ:INDP traded up $0.12 during trading on Friday, reaching $3.38. The stock had a trading volume of 138,087 shares, compared to its average volume of 2,955,560. Indaptus Therapeutics has a 1-year low of $0.92 and a 1-year high of $13.40. The stock has a market cap of $382.98 million, a PE ratio of -0.22 and a beta of 1.25. The business has a fifty day moving average price of $2.63 and a 200-day moving average price of $2.35.

Indaptus Therapeutics (NASDAQ:INDP) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.87) by $1.64.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.